Lipella Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 7
- Market Cap
- $3.7M
- Website
- http://www.lipella.com
Lipella Completes Enrollment in Phase IIa Trial for Novel Oral Lichen Planus Treatment
Lipella Pharmaceuticals has completed enrollment in its Phase IIa trial evaluating LP-310, a liposomal tacrolimus oral rinse, for treating oral lichen planus across three dose cohorts at seven US trial sites.
FDA Grants Expanded Access Program for Lipella's LP-310 in Oral Lichen Planus Treatment
The FDA has approved an Expanded Access Program for LP-310, an innovative oral rinse therapy targeting oral lichen planus, a condition affecting 6 million Americans with no current FDA-approved treatments.
Lichen Planus Pipeline Shows Promise with Emerging Therapies
A new report highlights the unmet need for targeted Lichen Planus (LP) treatments, as current options primarily offer palliative care.
Lipella's LP-310 Shows Positive Phase 2a Results for Oral Lichen Planus
Lipella Pharmaceuticals' LP-310, a liposomal-tacrolimus oral rinse, demonstrated statistically significant improvements in treating oral lichen planus (OLP).
Lipella Pharmaceuticals' LP-310 Shows Promise in Phase 2a Trial for Oral Lichen Planus
Lipella Pharmaceuticals completes the first cohort dosing in its Phase 2a trial of LP-310 for Oral Lichen Planus (OLP).
Lipella Pharmaceuticals' Liposomal Delivery Platform Secures U.S. Patent, Extending Market Exclusivity
Lipella Pharmaceuticals received U.S. Patent No. 12,138,345 for its liposomal drug delivery platform, enhancing targeted therapeutic agent delivery.